Funding for this research was provided by:
Seventh Framework Programme (305736)
Received: 22 February 2022
Accepted: 12 June 2022
First Online: 28 June 2022
: The study was approved by the regional ethical committee, the Danish Data Protection Agency and the Danish Medicines Agency. The study was conducted in accordance with the Good Clinical Practice guidelines [CitationRef removed], and with regular monitoring by the local clinical research organization from the Good Clinical Practice unit. All participants were given information regarding the project and their rights as a research participant both orally and in writing. Participants were asked to supply written consent before they were enrolled in the study.
: Permission from the individual participant has been attained before publication of personal data and images contained in this manuscript.
: TOB is an equity holder and director of Orbson Therapeutics Ltd. The remaining authors does not have any competing interest related to this work. Outside of this work: MFM has received speaking fees from Boehringer Ingelheim, Novartis, Baxter and Sanofi SE is employed in Novo Nordisk A/S. KKM has received consultancy and/or speaking fees from Coloplast, Mölnlycke, SoftOx A/S and Bayer Pharmaceuticals AG. PR has received consultancy and/or speaking fees (to SDCC) from AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, Eli Lilly, MSD, Novo Nordisk and Sanofi Aventis, and research grants from Novo Nordisk and Astra Zeneca.